Alembic Pharma started FY27 with a strong first quarter. The company reported healthy growth in profit and revenue. Its performance was supported by new product launches, volume growth, and steady execution across key markets.
Quarterly Earnings took the spotlight after Pfizer reported better-than-expected second-quarter results. However, the company made it clear that its focus extends beyond one strong quarter.
Drug approvals and pharma manufacturing continue to shape the pharmaceutical landscape as new research, regulatory developments, and financial results drive industry momentum
Ebola treatment efforts intensify as the WHO accelerates clinical trials in response to the outbreak in the Democratic Republic of the Congo
Biocon has entered the US eye drug market with the commercial launch of Yesafili, its aflibercept biosimilar to Eylea.
Retatrutide Early Access has started for a limited group of patients before its expected FDA approval. Eli Lilly has launched an expanded access program for eligible adults with severe obesity.
Surgical drug innovation takes center stage as Dr. Reddy’s Laboratories expands its US portfolio with the launch of Sugammadex injection
The dental implant safety framework is under consideration by the Central government as concerns grow over the quality, regulation, and long-term safety of dental implants used across India.
Drug launches, pharma policy, and healthcare investment trends continue to reshape the global and Indian pharmaceutical landscape
Bike ambulance services will gain regulatory clarity as India drafts new rules to strengthen emergency response systems, the proposal also introduces standards to ensure construction, safety, and functional compliance
, CDSCO.jpg "Fostering a Quality Culture in the Pharmaceutical Industry")